Last reviewed · How we verify
NCT06051409
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
Phase 3 trial testing Olverembatinib in Ph+ ALL in 350 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Ascentage Pharma Group Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 31 August 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 October 2028 |
| Sites | 14 locations across China, Australia |
Drugs / interventions tested
- Olverembatinib — full drug profile →
- Imatinib — full drug profile →
Conditions studied
- Ph+ ALL — all drugs for Ph+ ALL →
Sponsor
Ascentage Pharma Group Inc. — full company profile →
Who can join
18 and older, any sex, with Ph+ ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of Olverembatinib combined with chemotherapy versus Imatinib combined with chemotherapy in subjects with newly diagnosed Ph+ALL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06051409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olverembatinib
Trials testing the same drug.
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07493161 — Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL · NA · not yet recruiting
- NCT06757855 — Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML · Phase 1, PHASE2 · recruiting
- NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
- NCT06401603 — A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph · Phase 1 · recruiting
Other Ascentage Pharma Group Inc. trials
Trials by the same sponsor.
- NCT07282093 — Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment · Phase 1 · recruiting
- NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
- NCT06389292 — A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia · Phase 3 · recruiting
- NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
- NCT05773586 — A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06051409 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ascentage Pharma Group Inc.
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06051409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing